User Bar First

This is a debugging block

User Bar Second

This is a debugging block

Header First

This is a debugging block

Pursuing Medical
Breakthroughs from
World's Leading Researchers

Finding Cures and
Innovative Treatments
Is Our Passion

Developing
First-in-Class Products

Header Second

This is a debugging block

Preface First

This is a debugging block

Preface Second

This is a debugging block

Preface Third

This is a debugging block

home

Content

This is a debugging block

Smiling Researcher

Millions of people all over the world have diseases for which there is no known treatment. For Laurantis researchers, management, and investors, those with unmet medical needs serve as our reminder that breakthrough treatments are good for society and good for business.

Laurantis Pharma Oy is a specialty pharmaceutical company developing first-in-class products for inflammatory disorders and secondary lymphedema.

Based on two proprietary technologies (cis-UCA and Ad-VEGF-C), our pipeline is focused on addressing unmet needs in dry eye, atopic dermatitis and secondary lymphedema in women after breast cancer treatment.

Learn more about Laurantis

Postscript First

This is a debugging block

Technologies

Modulation of cellular pH using cis-urocanic acid (cis-UCA)

Laurantis Pharma’s anti-inflammatory drug developments are based on the use of cis-urocanic acid (cis-UCA) to modulate intracellular pH. Cis-UCA, an endogenous amino acid derivative, is a...

Delivery of vascular endothelial growth factor C (VEGF-C) using an adenoviral vector

Laurantis Pharma’s lymphedema drug development is based on vascular endothelial growth factor C (VEGF-C). VEGF-C is the only known growth factor that is both potent and specific enough...

Postscript Second

This is a debugging block

Products

A topical, semi-solid formulation that contains cis-urocanic acid (cis-UCA) as its active ingredient.

Non-steroidal cis-UCA emulsion cream, which addresses both the acute and chronic components of inflammation, is being...

A mildly viscous eye drop solution that contains cis-urocanic acid (cis-UCA) as its active ingredient.

Cis-UCA eye drops are being developed as a first-line treatment for ocular surface inflammation associated with moderate...

A vascular endothelial growth factor C (VEGF-C) gene in an adenoviral vector for the treatment of secondary lymphedema.

Lymfactin™ addresses the underlying cause of lymphedema, damage to the lymphatic vasculature, and consequently has the...

Postscript Third

This is a debugging block

Newsroom

03/12/12

About one in five women has painful swelling following breast cancer surgery. There are currently only limited options for dealing with this...

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy (“Laurantis Pharma”), a...

Lymphedema Awareness Day was established to support the needs of patients with lymphedema and to raise awareness for the need to develop new...

Postscript Fourth

This is a debugging block